What is the prevalence of Isovaleric acidemia?

TL;DR: Isovaleric acidemia is a rare metabolic disorder with an estimated global incidence ranging from 1 in 50,000 to 1 in 250,000 live births, though true prevalence is likely higher due to underdiagnosis. It affects males and females equally and can present as either a severe neonatal-onset form or a milder, intermittent form that may not be diagnosed until childhood or adulthood.

How common is Isovaleric acidemia?

Isovaleric acidemia is considered a rare metabolic disorder. Because it is an autosomal recessive condition, its prevalence is closely tied to the frequency of the underlying genetic mutation in specific populations. While global incidence is often cited between 1:50,000 and 1:250,000, these numbers are estimates derived from newborn screening programs. In regions without universal screening, isovaleric acidemia is likely significantly underreported. Currently, 23 people with isovaleric acidemia have joined the DiseaseMaps.org community, providing a vital real-world perspective on the lived experience of this condition beyond clinical statistics.

Are there geographic or demographic differences in prevalence?

Isovaleric acidemia does not exhibit a significant gender bias, affecting males and females with equal frequency. However, there are observed geographic and ethnic variations. For example, higher incidences have been reported in certain populations, such as in parts of Germany and Saudi Arabia, where founder effects or higher rates of consanguinity may influence carrier frequency. Because isovaleric acidemia is inherited in an autosomal recessive pattern, the prevalence is higher in communities where relatedness between parents is more common.

What are the challenges in determining accurate prevalence data?

Determining the exact prevalence of isovaleric acidemia remains a challenge for several clinical reasons:

• Asymptomatic or Milder Cases: Some individuals with isovaleric acidemia have a milder phenotype, meaning they may experience only intermittent symptoms that are never clinically investigated.


• Diagnostic Delays: Without mandatory newborn screening (NBS), many infants may pass away from metabolic crisis before a diagnosis is ever confirmed, leading to an underestimation of the true birth incidence.


• Misdiagnosis: Early symptoms of isovaleric acidemia, such as poor feeding or lethargy, can mimic common neonatal infections (like sepsis), leading to potential misdiagnosis in clinical settings.

At what age does Isovaleric acidemia typically present?

The age of onset for isovaleric acidemia generally falls into two distinct categories:

1. Neonatal-onset form: This is the most severe presentation, typically occurring within the first few days of life, characterized by severe metabolic acidosis and hyperammonemia.


2. Chronic intermittent form: This form may present later in infancy or even adulthood, often triggered by metabolic stress such as illness, fasting, or high-protein intake.

Next steps

• Consult a metabolic specialist or a medical geneticist to discuss testing if you suspect isovaleric acidemia.


• If you or a loved one have been diagnosed, consider joining the DiseaseMaps.org community to connect with other patients and share experiences.


• Request a referral to a metabolic dietitian who specializes in the long-term protein management required for isovaleric acidemia.


• Monitor the NIH GARD website for updates on clinical trials and research advancements.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Isovaleric acidemia.


• Orphanet: Isovaleric acidemia (ORPHA:45).


• OMIM (Online Mendelian Inheritance in Man): Isovaleric acidemia (Entry #243500).


• National Organization for Rare Disorders (NORD): Isovaleric acidemia report.